DP-4088(DP-4088) - 药物靶点：thrombin_专利_临床

概要

基本信息

药物类型

小分子化药

别名

DP 4088、DPOC-4088

靶点

thrombin

作用机制

thrombin抑制剂(激活型凝血因子II抑制剂)

治疗领域

心血管疾病血液及淋巴系统疾病

在研适应症-

非在研适应症

心房颤动凝血障碍静脉血栓形成

原研机构

Merck & Co., Inc.

在研机构-

非在研机构

Diakron Pharmaceuticals, Inc.

Merck Sharp & Dohme Corp.

Orchid Pharma Ltd.

+ [1]

最高研发阶段终止临床1期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

结构

分子式C19H16ClF3N6O2

InChIKeyAATHXZYXWMKUFC-UHFFFAOYSA-N

CAS号312904-62-4

关联

2

项与 DP-4088 相关的临床试验

NCT01647620 / Terminated临床1期

A Randomized, Double-blind, Placebo-controlled, Stepwise Study of the Pharmacokinetics (PK), Pharmacodynamics (PD), PK/PD Characteristics and Safety of Multiple Once-daily Oral Dosing of DPOC-4088 in Healthy Young Male Subjects

A study to investigate the concentrations of a new drug DPOC-4088 in blood, and to study the effect of this drug on blood clotting parameters. Furthermore the relation between the blood concentrations and the blood clotting effect will be investigated. Safety will be investigated as well. The objective of these investigations is to determine the optimal dose of DPOC-4088 that, achieves a relevant increase in a specific blood clotting parameter (the ecarin clotting time) without safety concerns.

开始日期2012-02-01

申办/合作机构

Diakron Pharmaceuticals, Inc.

[+1]

NCT01347203 / Completed临床1期

A Randomized, Open-label, 4-period Crossover Study to Evaluate the Pharmacokinetics (PK), Pharmacodynamics (PD) and the PK/PD Relationship of DPOC-4088 After Single Oral Dosing of 100 and 200 mg in 2 Prolonged Release Formulations (16 and 20 hr) in 12 Healthy Young Male Subjects

This will be a study existing of 4 periods, to evaluate for a single dose of 4 different tablets of DPOC-4088 the absorption and elimination from the body and the potential effect on blood clotting. The differences between the tablets are the dose (100 or 200 mg) and the rate of release of DPOC-4088 from the tablet (16 or 20 hours). The allocation of the tablets in each period will be determined by chance but is known upfront.

开始日期2011-04-01

申办/合作机构

Diakron Pharmaceuticals, Inc.

100 项与 DP-4088 相关的临床结果

登录后查看更多信息

100 项与 DP-4088 相关的转化医学

登录后查看更多信息

100 项与 DP-4088 相关的专利（医药）

登录后查看更多信息

100 项与 DP-4088 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
心房颤动	临床1期	比利时	Diakron Pharmaceuticals, Inc.	2012-02-01
静脉血栓形成	临床1期	美国	Diakron Pharmaceuticals, Inc.	2008-08-13
静脉血栓形成	临床1期	印度	Orchid Pharma Ltd.	2008-08-13
凝血障碍	临床1期	比利时	Diakron Pharmaceuticals, Inc.	-
凝血障碍	临床1期	-	Orchid Website Design Ltd.	-
凝血障碍	临床1期	-	Merck Sharp & Dohme Corp.	-